ArticleCurrent developments in nutrition2026
The Economic Implications of Relapse Among Children Recovered from Severe Acute Malnutrition: Results from a Multicountry Prospective Study in Mali, Somalia, and South Sudan.
Article in Current developments in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The community-based management of acute malnutrition (CMAM) is effective at recovering children from severe acute malnutrition (SAM) and saving lives. However, postdischarge, children may relapse to acute malnutrition (AM), thereby requiring retreatment. Objectives: This study aims to assess the economic implications of treating children who relapse to AM within 6 mo of recovering from initial treatment for uncomplicated SAM in CMAM programs. Methods: This study was part of a multicountry prospective cohort study in which children aged 6-47 mo with uncomplicated SAM were followed for 6 mo after recovery in Mali, Somalia, and South Sudan (SSD). Institutional cost data were collected monthly through accounting records or key informant interviews, depending on data availability. Mean costs per treatment episode for each CMAM program component were calculated (initial SAM recovery, relapse to SAM treatment, relapse to moderate AM treatment; 2022 USD). Results: The cost per child of recovery in initial SAM treatment was $191, $92, and $178 in Mali, Somalia, and SSD, respectively. The cost per child who failed to sustain recovery and required treatment for relapse to SAM was 1.7-2.2 times higher than initial recovery, amounting to an additional $215, $64, and $215/child in Mali, Somalia, and SSD, respectively. Not having to retreat children would save per admitted child on mean $2 in Somalia, $26 in SSD, and $45 in Mali. Conclusions: This is the first analysis to estimate the cost of retreating children who relapse to AM within 6 mo of recovering from SAM. Our findings show that the cost of treating relapse to SAM is, on mean, twice as high as the initial SAM recovery. Preventing relapse could free up significant resources. Amid reduced global assistance, these results highlight the economic rationale for improving the efficiency of global nutrition programs by reducing relapse rates and strengthening prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.